403 related articles for article (PubMed ID: 34440731)
21. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
22. JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.
Soliman EA; El-Ghlban S; El-Aziz SA; Abdelaleem A; Shamaa S; Abdel-Ghaffar H
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e645-e651. PubMed ID: 32591258
[TBL] [Abstract][Full Text] [Related]
23. Low
Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
[No Abstract] [Full Text] [Related]
24. Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.
Calabresi L; Balliu M; Bartalucci N
Methods Cell Biol; 2022; 171():81-109. PubMed ID: 35953207
[TBL] [Abstract][Full Text] [Related]
25. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
26. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
[TBL] [Abstract][Full Text] [Related]
27. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
28. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
29. Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options.
Gotoh A
Int J Hematol; 2022 May; 115(5):616-618. PubMed ID: 35397744
[TBL] [Abstract][Full Text] [Related]
30. [Recent advances in the treatment of myelofibrosis].
Takenaka K
Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
32. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
Cazzola M; Kralovics R
Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
34. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
35. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
36. Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
Grinfeld J; Nangalia J; Baxter EJ; Wedge DC; Angelopoulos N; Cantrill R; Godfrey AL; Papaemmanuil E; Gundem G; MacLean C; Cook J; O'Neil L; O'Meara S; Teague JW; Butler AP; Massie CE; Williams N; Nice FL; Andersen CL; Hasselbalch HC; Guglielmelli P; McMullin MF; Vannucchi AM; Harrison CN; Gerstung M; Green AR; Campbell PJ
N Engl J Med; 2018 Oct; 379(15):1416-1430. PubMed ID: 30304655
[TBL] [Abstract][Full Text] [Related]
37. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Barbui T; Falanga A
Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
[TBL] [Abstract][Full Text] [Related]
38. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
39. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
[TBL] [Abstract][Full Text] [Related]
40. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Ferreira Cristina S; Polo B; Lacerda JF
Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]